纳米医学
程序性细胞死亡
癌细胞
GPX4
癌症研究
细胞凋亡
癌症
旁观者效应
化学
纳米技术
医学
氧化应激
材料科学
免疫学
纳米颗粒
生物化学
内科学
谷胱甘肽过氧化物酶
过氧化氢酶
作者
Yanhong Su,Bing Liu,Binghan Wang,Leung Chan,Chan Xiong,Ligong Lu,Xuanjun Zhang,M Zhan,Weiling He
出处
期刊:Small
[Wiley]
日期:2024-01-14
卷期号:20 (25)
被引量:10
标识
DOI:10.1002/smll.202310342
摘要
Abstract Ferroptosis is a new form of regulated cell death featuring iron‐dependent lipid peroxides accumulation to kill tumor cells. A growing body of evidence has shown the potential of ferroptosis‐based cancer therapy in eradicating refractory malignancies that are resistant to apoptosis‐based conventional therapies. In recent years, studies have reported a number of ferroptosis inducers that can increase the vulnerability of tumor cells to ferroptosis by regulating ferroptosis‐related signaling pathways. Encouraged by the rapid development of ferroptosis‐driven cancer therapies, interdisciplinary fields that combine ferroptosis, pharmaceutical chemistry, and nanotechnology are focused. First, the prerequisites and metabolic pathways for ferroptosis are briefly introduced. Then, in detail emerging ferroptosis inducers designed to boost ferroptosis‐induced tumor therapy, including metal complexes, metal‐based nanoparticles, and metal‐free nanoparticles are summarized. Subsequently, the application of synergistic strategies that combine ferroptosis with apoptosis and other regulated cell death for cancer therapy, with emphasis on the use of both cuproptosis and ferroptosis to induce redox dysregulation in tumor and intracellular bimetallic copper/iron metabolism disorders during tumor treatment is discussed. Finally, challenges associated with clinical translation and potential future directions for potentiating cancer ferroptosis therapies are highlighted.
科研通智能强力驱动
Strongly Powered by AbleSci AI